Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Acurx Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Acurx Pharmaceuticals şirketinin kazançları yıllık ortalama -22.2% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.7% oranında arttı.

Anahtar bilgiler

-22.2%

Kazanç büyüme oranı

-2.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-488.1%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely

Aug 11

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release

Jan 22

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Oct 30

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Jul 15

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Mar 04

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Nov 16

Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering

Jul 25

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

May 13

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Jan 22

Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

Sep 30

New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers

Aug 27

Gelir ve Gider Dağılımı

Acurx Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:ACXP Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	-17	10	7
31 Mar 24	-16	9	7
31 Dec 23	-15	9	6
30 Sep 23	-13	7	6
30 Jun 23	-13	7	6
31 Mar 23	-12	7	5
31 Dec 22	-12	7	5
30 Sep 22	-11	7	4
30 Jun 22	-13	9	4
31 Mar 22	-14	11	3
31 Dec 21	-13	11	2
30 Sep 21	-11	10	2
30 Jun 21	-8	7	1
31 Mar 21	-5	3	2
31 Dec 20	-5	2	2

Kaliteli Kazançlar: ACXP şu anda kârlı değil.

Büyüyen Kar Marjı: ACXP şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ACXP kârlı değildir ve zararlar son 5 yılda yılda 22.2% oranında artmıştır.

Büyüme Hızlandırma: ACXP 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ACXP kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: ACXP hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -488.09% ) sahiptir.

Acurx Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Acurx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Acurx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 15, 2024

Acurx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Acurx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Acurx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Acurx Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 12, 2023

Recent updates

Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely

New major risk - Revenue and earnings growth

Insufficient new directors

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Price target decreased by 10% to US$10.88

Acurx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

New major risk - Revenue and earnings growth

Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

Forecast to breakeven in 2026

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global Scientific Conference

Acurx Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2024

Acurx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 15, 2024

Acurx Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering.

Acurx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Acurx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Acurx Pharmaceuticals, Inc. Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2B Clinical Trial in Cdi Patients

Independent Director exercised options to buy US$75k worth of stock.

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients

Co-Founder exercised options to buy US$77k worth of stock.

Acurx Pharmaceuticals, Inc. Announces Positive Phase 2B Results Showing 100% of Patients Who Has Clinical Cure with Ibezapolstat Also Has Sustained Clinical Cure

Acurx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $17 million.

New major risk - Financial position

Acurx Pharmaceuticals, Inc. Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. Difficile Infection

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Share price stability

Acurx Pharmaceuticals, Inc. Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

New major risk - Revenue and earnings growth

Acurx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Acurx Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 12, 2023

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Acurx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 16, 2022

Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI At the 16Th Biennial Congress of the Anaerobe Society of America

Acurx Pharmaceuticals, Inc. announced a financing transaction

Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering

Acurx Pharmaceuticals, Inc.(NasdaqCM:ACXP) dropped from Russell Microcap Value Index

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

Acurx Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022

Acurx Pharmaceuticals, Inc. Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Announces First Patient Enrolled in Phase 2B Clinical Trial of Its Lead Antibiotic for Treatment of Clostridioides Difficile Infection (CDI)

Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers

Acurx Pharmaceuticals, Inc. has completed an IPO in the amount of $15 million.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin